

B2
sub C2
cont

~~C~~

administering, at the time of tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal.

B3
sub C3

~~C~~

6. (Amended) A method of treating complement-mediated cytotoxicity in a mammal which comprises identifying a mammal with complement-mediated cytotoxicity and administering to said mammal a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal.

10. The method of claim 1 wherein said mammal is a human.

11. The method of claim 6 wherein said mammal is a human.

12. The method of claim 1 wherein said mammal has necrotic injury.

13. A method of treating necrotic injury in a mammal comprising identifying a mammal with necrotic injury; and administering to said mammal a therapeutically effective amount of interleukin-11.

14. The method of claim 13, wherein said mammal is a human.

15. The method of claim 13, wherein administering IL-11 is due to localized tissue or cell injury.
16. The method of claim 13, wherein said necrotic injury is caused by loss of blood supply, corrosion, burning, or local lesion of a disease.
17. The method of claim 14, wherein administering IL-11 is due to localized tissue or cell injury.
18. The method of claim 14, wherein said necrotic injury is caused by loss of blood supply, corrosion, burning, or local lesion of a disease.
19. The method of claim 13, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 $\mu\text{g/kg}$ body weight.
20. The method of claim 13, wherein the interleukin-11 is administered daily until improvement of necrotic injury is observed.